Bleeding Complications After Thrombolysis for Stroke

Introduction to Bleeding Complications

• The American Heart Association notes that bleeding complications after thrombolysis for acute ischemic stroke are categorized into intracranial hemorrhage and systemic hemorrhages, with intracranial hemorrhage being the most serious complication, occurring in approximately 6.4% of treated patients in the landmark NINDS trials 1, 2
• The American Stroke Association reports that symptomatic intracranial hemorrhage has mortality rates of 60% or more when it occurs post-thrombolysis, and is a major bleeding complication associated with thrombolytic therapy 3

Risk Stratification for Intracranial Hemorrhage

• The National Institute of Neurological Disorders and Stroke indicates that the NIHSS score is the strongest predictor of intracranial hemorrhage risk after thrombolysis, with patients having an NIHSS score >20 having a 17% risk of symptomatic intracranial hemorrhage, compared to only 3% in those with NIHSS <10 1, 2
• The American College of Cardiology states that other independent risk factors for intracranial hemorrhage include age >80 years 1, 2, deviation from national treatment protocols 1, 2, major early CT changes indicating extensive ischemia 4, blood pressure elevation 4, and blood glucose >200 mg/dL 4

Systemic Hemorrhages

• The American Heart Association notes that major systemic bleeding complications occur in approximately 1.6% of patients treated with IV rtPA, and include retroperitoneal hemorrhage, gastrointestinal hemorrhage, genitourinary hemorrhage, and hemopericardium 5
• The Society of Interventional Radiology reports that for patients undergoing endovascular thrombectomy, access site hemorrhage, pseudoaneurysm formation at access sites, and arterial closure device failure leading to bleeding are potential complications 5

Clinical Recognition and Monitoring

• The American Stroke Association recommends that hemorrhagic transformation should be suspected with any change in level of consciousness, elevation of blood pressure, deterioration in motor examination, onset of new headache, or nausea and vomiting 1, 2
• The National Institute of Neurological Disorders and Stroke suggests a monitoring protocol that requires blood pressure checks every 15 minutes for 2 hours, then every 30 minutes for 6 hours, then hourly until 24 hours, and neurological assessments every 15 minutes during infusion, every 30 minutes for 6 hours, then hourly until 24 hours 6

Risk Factors for Cerebral Bleeding After Thrombolysis for Stroke

Additional Considerations

• Unruptured intracranial aneurysms or arteriovenous malformations may increase hemorrhage risk, though limited data exists, with 2 fatal intracranial hemorrhages reported in 5 cases with intracranial aneurysm detected after intraarterial thrombolysis 7, 8
• The American Heart Association, as published in the journal Stroke, suggests that structural vascular abnormalities, such as unruptured intracranial aneurysms or arteriovenous malformations, may increase hemorrhage risk 7, 8

Clinical Context

• The American College of Chest Physicians recommends consideration of the overall rate of symptomatic intracranial hemorrhage, which ranges from 3-9% in acute ischemic stroke patients treated with tPA, with recent large studies showing rates of approximately 6.4-7.3% 9

Management of Post-Thrombolysis Intracranial Hemorrhage

Immediate Recognition and Stabilization

• If intracranial hemorrhage occurs after tPA administration, immediately stop the tPA infusion and initiate urgent empirical therapies to replace clotting factors and platelets, as recommended by the American Heart Association 10

Urgent Reversal of Fibrinolytic State

• Administer platelets (6-8 units) and cryoprecipitate containing factor VIII immediately to rapidly correct the systemic fibrinolytic state created by tPA, as recommended by the American Heart Association 10
• The 30-day mortality rate for post-thrombolysis intracranial hemorrhages is 60% or more, highlighting the need for rapid reversal of the coagulopathy, as stated by the American Heart Association 10

Blood Pressure Management

• Aggressive blood pressure control is critical to prevent hematoma expansion, and specific targets in the post-thrombolysis setting should follow general intracerebral hemorrhage guidelines, as recommended by the American Heart Association 10

Surgical Evaluation

• Surgical evacuation should only be considered after sufficient infusion of platelets and cryoprecipitate has stabilized intracranial bleeding, as recommended by the American Heart Association 10

Antiplatelet Management

• Hold all antiplatelet agents immediately, and do not restart them until the hemorrhage has stabilized and been reassessed with repeat imaging, as recommended by the International Stroke Society 11
• Avoid antithrombotic drugs, including aspirin, until after the 24-hour post-thrombolysis scan excludes intracranial hemorrhage, as recommended by the International Stroke Society 11

Prognosis

• The mortality rate for symptomatic intracranial hemorrhage after thrombolysis exceeds 60% at 30 days, highlighting the need for early recognition and aggressive reversal of the fibrinolytic state, as stated by the American Heart Association 10

Reversal of tPA-Related Intracranial Hemorrhage

Guideline-Based Recommendations

• The Neurocritical Care Society and Society of Critical Care Medicine recommend cryoprecipitate (10 units initial dose) as the first-line therapy for patients with thrombolytic agent-related symptomatic intracranial hemorrhage who received tPA within the previous 24 hours, based on low-quality evidence 12, 13
• The American Heart Association/American Stroke Association guidelines suggest infusion of platelets (6-8 units) and cryoprecipitate containing factor VIII to rapidly correct the systemic fibrinolytic state created by tPA, representing Class IIb evidence (Level B) 14
• The target fibrinogen level is ≥150 mg/dL, and if below target after initial therapy, additional cryoprecipitate should be given 12, 13

Alternative Therapies

• Antifibrinolytic agents (tranexamic acid 10-15 mg/kg IV over 20 minutes or ε-aminocaproic acid 4-5 g IV) are suggested as alternatives when cryoprecipitate is contraindicated or not available in a timely manner, based on very low-quality evidence 12, 13

Monitoring and Additional Therapy

• Fibrinogen levels should be checked after administering reversal agents, and if fibrinogen remains <150 mg/dL, additional cryoprecipitate should be administered 12, 13

Surgical Considerations

• Surgical evacuation should only be initiated after sufficient infusion of platelets and cryoprecipitate has stabilized bleeding, according to the American Heart Association/American Stroke Association guidelines 14